The problem of determining an oral dose, or schedule of oral doses, that gives rise to an arbitrary area-under-curve or to points on the time-series for a variable of interest in a drug kinetics model is considered. These two measures are considered as surrogates for the particular drug response to the dose. The approach taken is to formulate the problem as a fixed point one to which a version of the Contraction Mapping Theorem can be applied. The results, illustrated for a model for the anti-cancer agent topotecan, demonstrate the applicability of the approach.
that is important in determining the effect of the drug.
28
In this paper the problem of determining an optimal oral dose, or oral dos-29 ing schedule, for a drug kinetics model is considered. Optimality is regarded 30 with respect to either hit-on-target as represented by the AUC for a partic-31 ular times-series, or to achieving pre-defined points on a given time-series.
32
The approach taken is to reformulate the problem in such a way as to make 
36
The earliest use of fixed point methods in a control context was by Her-37 mes [7] for finite-dimensional systems. Davison and Kunze [8] describe the 38 application of fixed point methods to finite-dimensional time-varying sys-39 tems, and this approach has been extended to infinite-dimensional systems 40 by Magnusson and Pritchard [9] . Carmichael and Quinn [10] provide an early 41 review of the use of fixed point methods in nonlinear control and observation. Consider the problem of choosing a drug dose for a general drug kinetic 51 model of the following form:
such that a particular area-under-curve (AUC) value is obtained for the de- 
55
Suppose that an initial guess is made for the dose, =ˆ , which gives rise 56 to the following AUC value:
whereˆ ( ) is the solution of the initial value problem
Since this is unlikely to yield the desired value consider perturbations from 59 this solution; that is, set ( ) = ( ) −ˆ ( ) and = −ˆ in Equation (1) to 60 yield the following:
= where ( ) is the Jacobian matrix of (with respect to ) evaluated atˆ ( ).
62
With respect to this perturbed system the output of interest becomes:
Neglecting (for now) the nonlinearity, the problem corresponds to choosing 64 such that:
and (⋅, ⋅) is the state-transition matrix for the time-varying linear system.
66
Since is a number then the unique solution (for the linear system) is
67
given by:
Now considering the full nonlinear system this suggests choosing such that:
and so the choice for the dose is given by
This, however, gives an implicit relationship between * and the solution (which requires * ). To overcome this problem a fixed-point is sought of the following operator:
If is a fixed point of this operator, Ψ, then the AUC for the doseˆ + * is 72 then given by:
Thus the desired AUC is achieved for the doseˆ + * , provided there exists 74 a fixed point of the operator Ψ defined in (4).
75
Theorem 2. Suppose that the following are satisfied: 
84
If the AUC corresponding to the initial dose,ˆ , is close to the target value 85 in the sense that
then the operator Ψ in Equation (4) has a unique fixed point.
87
Proof. To see that Ψ is a contraction on the ball ( ) note that:
is contained within the ball ( ) provided 
102
Consider the problem with doses at regular intervals of starting at
103
= 0:
where 1 (0) = 0 + 1 and = 1, . . . , .
105
Proceeding in a similar manner as in the previous section, letˆ denote 106 initial guesses for the doses, which give rise to output time series of the form:
whereˆ ( ) is the solution of the initial value problem given by (6)- (7) with . . .
The matrix ∈ ℝ × is unlikely to be invertible and so the least squares 118 solution is chosen:
where † is the pseudo-inverse of . Now considering the full nonlinear system, let
.
Then the linear approach suggests choosing such that:
but, as in the last section this leads to an implicit equation for (the solution on [0, ], = × , obtained by piecing together the ). Again, to overcome this a fixed-point is sought of the following operator, Ψ:
where † is the th row of † .
122
If a fixed-point of Ψ exists then the output corresponding to the fixed 123 point is given by:
Hence the difference between the achieved profile and the target profile is
125
where the right-hand side is the orthogonal projection onto (ran ) ⊥ . Thus
127
it is seen that the reference profile is matched on the range of .
128
To illustrate the application of the fixed point theorem to the problem 
If the target profile, d , is close to that corresponding to the initial dose,ˆ ,
141
in the sense that
then the operator Ψ in (9) (single-dose case) has a unique fixed point.
143
and be the ball
is contained within the ball ( ) provided
which is guaranteed by (10) . Applying Theorem 1 proves the required result. 
then the operator Ψ in (9) has a unique fixed point.
159
Proof. First note that on the ball ( ):
for suitable constants 1 and 2 , where = sup 0≤ , ≤ ℎ( , ). Therefore,
it is seen that Ψ is a contraction on ( ).
163
Let = 0, = Ψ so that
is contained within the ball ( ) provided (11) is satisfied. Applying
166
Theorem 1 proves the required result. 
196
The model equations are as follows:
where 0 = / is the ratio of the volumes of the extracellular pool ( ) and The problem is to choose the dose . The first problem considered is to achieve an AUC for , over a one 
AUC: Multiple doses

225
Suppose that it is necessary, in the previous problem, to limit the peak 226 concentration of bound drug ( ) or to limit the administered dose at any bound drug is shown in Figure 2 where the profile is seen to maintain a much 266 more constant level than the single or double dose cases.
267
It should be noted that this method does not exploit the fact that at the 268 end of any given dosing period there is drug stored within the compartments
269
and that the amount of drug present is dependent on all of the previous doses.
270
Although an approach based on that taken with the time-series problem in active drug is plotted in Figure 6 , together with the target points. Again,
313
there is good correspondence between the time series for the dosing scheme 314 and the target.
315
It was seen in Section 3 that the method for finding the required dose 316 is guaranteed to achieve the required profile on the range of the matrix 
